Core Viewpoint - 康诺亚-B (02162) shares rose over 4% following the announcement that its self-developed drug 康悦达® (司普奇拜单抗注射液) has been included in the National Basic Medical Insurance Drug List for 2025, effective from January 1, 2026 [1]. Group 1: Company Developments - 康诺亚 announced that its drug 康悦达® (司普奇拜单抗) is the first domestically developed IL-4Rα humanized monoclonal antibody approved for market, targeting type 2 inflammatory diseases through dual blockade of the IL-4/IL-13 signaling pathway [1]. - The drug has received approval for three indications: moderate to severe atopic dermatitis in adults inadequately controlled by topical medications, chronic rhinosinusitis with nasal polyps inadequately controlled by corticosteroids and/or surgery, and moderate to severe seasonal allergic rhinitis in adults inadequately controlled by nasal corticosteroids combined with antihistamines [1]. Group 2: Market Impact - Following the announcement, 康诺亚-B's stock price increased by 4.23%, reaching 61.6 HKD, with a trading volume of 1.3244 million HKD [1].

Core Viewpoint - Junshi Biosciences (01877) has seen a stock price increase of 1.87% to 24 HKD following the announcement of new indications for its products being included in the National Medical Insurance Directory [2][5]. Group 1: Product Developments - Junshi Biosciences announced that its product Toripalimab injection (brand name: Tuoyi®, product code: JS001) has received two new indications, and its product Engreztinib injection (brand name: Junshida®, product code: JS002) has been successfully included in the National Medical Insurance Directory (2025) under the Class B category [2][5]. - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026 [2][5]. Group 2: Product Portfolio - As of the announcement date, four commercialized products from the company, including Tuoyi®, Adalimumab injection (brand name: Junmaikang®, product code: UBP1211), Dexamethasone Hydrochloride Tablets (brand name: Mindewi®, product code: VV116/JT001), and Junshida®, have all been included in the National Medical Insurance Directory [2][5]. - Tuoyi® is the only anti-PD-1 monoclonal antibody in the directory that is approved for treating renal cancer, triple-negative breast cancer, and melanoma, with all 12 approved indications included [2][5]. - Junshida® is newly included and is the only domestic PCSK9-targeted drug in the new directory for patients intolerant to statins [2][5].

Core Points - The company has successfully included several of its products in the National Medical Insurance Catalog for 2025, which is expected to enhance sales and improve operational performance [1] - The total estimated sales for the included drugs in 2024 is approximately 8.66 billion yuan, and for the first three quarters of 2025, it is about 7.55 billion yuan [1] Drug Inclusion in National Medical Insurance Catalog - The following drugs have been newly included: - Injection of Rukang Qutuzumab - Apixaban Famitinib Capsules - Injection of Funaqi Zhumab - Sulfate of Amatuximab Tablets - Injection of Phosphorola Pitant Palonosetron - Injection of Ruikasi Zhumab - Acetate of Abiraterone Tablets (II) - Lipid Injection of Irinotecan Hydrochloride (II) - Regaglitin Metformin Tablets (I)/(II) - Perfluorohexyl Octane Eye Drops [1] - The following drugs have successfully added new indications: - Injection of Karelizumab - Fluorazepam Capsules - Injection of Fumaric Acid Tegafur [1] - The following drugs have been renewed and retained in the National Medical Insurance Catalog: - Maleate of Pyrotinib Tablets - Hecorapam Ethanolamine Tablets - Phosphate of Regaglitin Tablets - Injection of Methylsulfonylmethane Remazolam - Sulfate of Pevonedistat Injection [1] - The following drugs have new indications and have been adjusted to regular catalog management: - Mesylate of Apatinib Tablets - Lipid Injection of Bupivacaine [1] Impact on the Company - The inclusion of these drugs in the National Medical Insurance Catalog is expected to positively impact sales, although the exact effect on the company's operational performance is currently indeterminate [1] - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with further details on payment standards and reimbursement rules to be announced by relevant government departments [1]

Core Viewpoint - Heng Rui Medicine has successfully included several of its products in the National Medical Insurance Catalog for 2025, which is expected to enhance sales and positively impact the company's performance in the future [1][2]. Group 1: Inclusion in National Medical Insurance Catalog - Heng Rui Medicine's products such as injection of Rukang Trastuzumab, Apixaban capsules, and others have been newly included in the National Medical Insurance Catalog [1]. - Additional indications for products like injection of Carrelizumab and Fluorouracil capsules have also been successfully added to the catalog [1]. - Existing products such as Pyrotinib tablets and others have successfully renewed their contracts to remain in the National Medical Insurance Catalog [1]. Group 2: Financial Impact - The total sales for the aforementioned drugs in 2024 are estimated to be approximately 8.66 billion yuan, while for the first three quarters of 2025, the sales are projected to be around 7.55 billion yuan [2]. - The impact on the company's operating performance due to the inclusion in the National Medical Insurance Catalog is currently indeterminate [2]. - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with further details on payment standards and reimbursement guidelines to be announced by relevant government departments [2].

每经AI快讯，12月7日，君实生物(688180.SH)公告称，公司产品特瑞普利单抗注射液(商品名：拓益)2项 新增适应症和昂戈瑞西单抗注射液(商品名：君适达)成功纳入《国家基本医疗保险、生育保险和工伤保 险药品目录(2025年)》乙类范围。新版国家医保目录将于2026年1月1日起正式实施。拓益已在中国内陆 获批的12项适应症全部纳入国家医保目录，是目录中唯一用于肾癌、三阴性乳腺癌和黑色素瘤治疗的抗 PD-1单抗药物；君适达为首次纳入，是新版目录中唯一用于他汀不耐受人群的国产PCSK9靶点药物。 这体现了国家医保局对上述药物的认可，有助于提高患者用药的可负担性和可及性，推动商业化产品的 市场推广和销售规模提升。 ...

Core Points - The current national medical insurance directory includes over 230 types of anti-cancer drugs [1] - These drugs cover more than 20 common types of cancer, including lung cancer, breast cancer, and stomach cancer [1] - The directory encompasses chemotherapy drugs, targeted therapy drugs, and immunotherapy drugs [1]